ABBVAbbvie Inc

AbbVie (ABBV) closed at $256.18 in the latest trading session, marking a +1.11% move from the prior day.

At Holdings Channel, we have reviewed the latest batch of the 51 most recent 13F filings for the 06/30/2026 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 30 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea...

Investors named Johnson & Johnson, Merck, Pfizer, AbbVie, Eli Lilly and Bristol Myers as possible bidders.

Key PointsAbbVie will fund this acquisition with debt, leaving its cash reserves intact...

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.69% on an annualized basis producing an average annual return of 14.83%. Currently, AbbVie has a market capitalization of $454.46 billion.read more...

Allergan Aesthetics receives approval for Boey (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients Allergan Aesthetics receives approval for Boey (trenibotulinumtoxinE), for use in...

ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31.

ABBV stock rallies 9% YTD as Skyrizi and Rinvoq offset Humira declines, but can its pipeline, neuroscience growth and Apogee deal sustain long-term momentum?

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.